Articles

Discover cutting-edge retinal technologies and treatments at the FLORetina International Congress in Florence, featuring top exhibitors and expert presentations.

Phakic IOLs deliver a “wow” factor to refractive surgery patients, says Matteo Piovella, MD

The two meetings will be held concurrently from December 4-7 in Florence, Italy

Expanding accessibility in ophthalmic training does not require expensive, intricate programming, but reasonable, simple actions from senior clinicians

Clinicians must assume responsibility for this common surgical concern

AnnMarie Hipsley, DPT, PhD, explores innovative approaches in ocular biomechanics, shifting focus from lenses to holistic treatments for presbyopia, enhancing vision care.

Inder Paul Singh, MD, discusses groundbreaking findings on the iDose implant's efficacy and safety in glaucoma management during cataract surgery.

David A. Eichenbaum, MD, FASRS, discusses findings on UBX-1325 for diabetic macular edema, highlighting a shift towards personalized, multi-mechanism therapies.

Chhablani discusses key findings on retinal vasculitis from the FAERS database, highlighting trends and safety in intravitreal treatments.

Kenneth C. Fan, MD, discusses promising visual improvements from MCO-010 therapy for Stargardt disease at AAO 2025, highlighting future treatment potential.

Stephen Tsang, MD, PhD, reviews promising optogenetic therapy results for retinitis pigmentosa and Stargardt disease, enhancing vision and mobility for patients.

James Chelnis explores innovative energy-based technologies in aesthetic facial surgery, emphasizing safety, personalized treatments, and future advancements in patient care.

Karolinne M. Rocha, MD, PhD, shares advancements in vision correction and patient satisfaction at the AAO 2025 meeting.

The EXTEND trial provided 5-year follow-up for 10 patients with advanced retinitis pigmentosa, who had previously received MCO-010 during a phase 1/2a trial

Data suggests that EYP-1901 can reduce the number of injections and treatment burden for patients

Adverum Biotechnologies is known for its therapeutic candidate Ixo-vec, in development for the treatment of wet age-related macular degeneration (AMD)

Both business moves further align Topcon with a long-term strategy for promoting data-driven predictive healthcare

The professor from Wills Eye Hospital in Philadelphia, Pennsylvania, explained why it's time to retire the term "sterile" when addressing culture-negative endophthalmitis

SPVN20 is a gene-agnostic, intravitreal AAV-based gene therapy that targets dormant cones to restore vision, according to SparingVision

A mutation-agnostic gene therapy approach offers new possibilities for patients, especially those with inherited retinal diseases

The satellite of the US-based University of Miami Health System will offer a “full spectrum of ophthalmic services” in the United Arab Emirates

A recently-updated textbook details major developments in therapeutic and cosmetic keratopigmentation, including superficial and intrastromal techniques

Reporting from the European Society of Retina Specialists annual congress

Providers are rethinking their spaces and systems to streamline care, reduce waste, and improve patient, staff and physician satisfaction